title: Treatment of type III hyperlipoproteinemia with gemfibrozil to retard progression of coronary artery disease.
abstract: Eight type III hyperlipoproteinemic (type III HLP), homozygous E 2/2 patients were enrolled in two periods of long-term diet-gemfibrozil treatment. The combined therapy resulted in highly significant decreases in their low-density lipoprotein cholesterol, very-low density lipoprotein cholesterol, very-low density lipoprotein triglycerides, and increases in their high-density lipoprotein cholesterol during the first treatment period of 24 to 28 months. Type III HLP reasserted itself following an 8-week interruption of gemfibrozil therapy. Resumption of gemfibrozil therapy again lowered the high lipid-lipoprotein concentrations of these patients toward normal. Tuboeruptive xanthomata, palmar xanthoma, and xanthoma striata palmare subsided with treatment. Follow-up coronary arteriograms performed 2.5 to 3.0 years after initiation of diet-drug treatment showed stabilization of coronary arterial lesions, which was associated with improvement in exercise tolerance.
authors.affiliation: Department of Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School, New Brunswick.
authors.forename: P T
authors.initials: PT
authors.lastname: Kuo
authors.forename: A C
authors.initials: AC
authors.lastname: Wilson
authors.forename: J B
authors.initials: JB
authors.lastname: Kostis
authors.forename: A B
authors.initials: AB
authors.lastname: Moreyra
authors.forename: H T
authors.initials: HT
authors.lastname: Dodge
mesh_terms: D000328:Adult; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000209:etiology / Q000517:prevention & control*; D004341:Drug Evaluation; D005080:Exercise Test; D005260:Female; D015248:Gemfibrozil; D006229:Hand Dermatoses / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006952:Hyperlipoproteinemia Type III / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy*; D000960:Hypolipidemic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008055:Lipids / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D008297:Male; D008875:Middle Aged; D010421:Pentanoic Acids / Q000009:adverse effects / Q000627:therapeutic use*; D014631:Valerates / Q000627:therapeutic use*; D014973:Xanthomatosis / Q000209:etiology / Q000517:prevention & control
chemical_list: D000960:Hypolipidemic Agents; D008055:Lipids; D008074:Lipoproteins; D010421:Pentanoic Acids; D014631:Valerates; D015248:Gemfibrozil